Crossmark

A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS

Published Online: 2021-02-06

Published Print: 2021-12

Authors

Gu, Siyu

Xia, Jingya

Tian, Yulu

Zi, Jie

Ge, Zheng http://orcid.org/0000-0001-8028-1612
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81770172)

Jiangsu Provincial Special Program of Medical Science (BE2017747)

Jiangsu Province "333" project (BRA2019103)

Fundamental Research Funds for the Central Universities (2242019K3DZ02)

Milstein Medical Asian American Partnership (MMAAP) Foundation Research Project Award in Hematology (2017)

Key Medical of Jiangsu Province (ZDXKB2016020)
License Information

Text and Data Mining valid from 2021-02-06

Version of Record valid from 2021-02-06
More Information

Article History

Received: 8 September 2020

Accepted: 1 February 2021

First Online: 6 February 2021

Ethics approval and consent to participate

: The written informed consent was provided by all the patients by the Declaration of Helsinki before enrollment in the study. The Institutional Review Board of Zhongda Hospital Southeast University, Nanjing, China, approved the study with approval number: 2017ZDKYBA001.0, 2017ZDKYBA002.0, 2019ZDSYLL033-P02.

: Not Applicable.

: The authors declare that they have no competing interests.

Document is current